J&J Keeps Cheap Risperdal Off Shelves

Law360, New York (May 11, 2007, 12:00 AM EDT) -- In a win for Johnson & Johnson, a U.S. appeals court has upheld a ban on the sale of a cheap version of the pharmaceutical giant’s antipsychotic drug Risperdal for the life of its key patent.

The victory was sweetened by news this week that the U.S. Food and Drug Administration had extended the patent’s life by six months after granting the company pediatric exclusivity to market its blockbuster medication.

The dark cloud in an otherwise sunny week for the drug maker was revealed in a...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.